{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:53:02Z","timestamp":1790103182590,"version":"4.0.1"},"reference-count":4,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p>Currently available treatment options for non-infectious scleritis, including non-steroidal anti-inflammatory drugs, systemic corticosteroids and immunosuppressive therapies, have both efficacy and side effect limitations. Iontophoretic delivery of corticosteroids has been demonstrated to be effective for anterior uveitis and represents a potential new approach to scleritis therapy. We hypothesised that iontophoretic delivery would provide effective and precise medication delivery to the sclera, while limiting systemic exposure and side effects. This first-in-human randomised, double-masked, dose-escalating study of iontophoretic administration of dexamethasone phosphate for scleritis suggests the treatment to be well tolerated and safe (within the limitations of the 18 patients sample size). There was a suggestion of efficacy in the lowest (1.2 mA\/min at 0.4 mA) dose group (corresponding to the superficial location of scleritis compared with anterior uveitis), with 5\/7 eyes meeting the primary efficacy outcome within 28 days. Our results suggest iontophoretic delivery of corticosteroids is a promising potential treatment for scleritis, with favourable safety and preliminary efficacy results in this phase 1 trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT01059955\" ext-link-type=\"clintrialgov\">NCT01059955<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-311610","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T20:28:40Z","timestamp":1536179320000},"page":"1011-1013","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial"],"prefix":"10.1136","volume":"102","clinical-trial-number":[{"clinical-trial-number":"nct01059955","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01059955","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Erin C","family":"O\u2019Neil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B","family":"Suhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P","family":"Dunn Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Gritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"McWilliams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Peskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-shuang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vatinee Y","family":"Bunya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen G","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2967-4792","authenticated-orcid":false,"given":"John H","family":"Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"2020050713014876000_102.8.1011.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(93)31473-9"},{"key":"2020050713014876000_102.8.1011.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.05.008"},{"key":"2020050713014876000_102.8.1011.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.07.006"},{"key":"2020050713014876000_102.8.1011.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.1991.tb00663.x"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-311610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:56:54Z","timestamp":1601110614000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-311610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":4,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,7,19]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1136\/bjophthalmol-2017-311610"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311610","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]}}}